Global cholesterol-lowering drugs market set to grow to $23bn by 2021
Visiongain’ has launched a new pharma report entitled Global Cholesterol-Lowering Drugs Market 2017-2027: Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs.
To read the report Table of contents please click on this link: https://www.visiongain.com/Report/1980/Global-Cholesterol-Lowering-Drugs-Market-2017-2027
Shifting diets and lifestyle choices are associated with increases in wealth and the level of development of a country’s economy. With the rapid growth seen in markets such as the BRIC markets, as well as other nations such as Mexico, rates of high cholesterol have been increasing in these nations. Many of the drugs currently used for the control of cholesterol levels have or are soon going to see their patents expire, allowing for generic competition. This has been particularly prevalent among statins, as many of these were developed some time ago.
There is a strong pipeline for cholesterol-lowering drugs; many of which will launch within the next two to three years. New drug classes such as PCSK9 inhibitors will open up new areas of treatment, as they allow further treatment of patients with very high cholesterol levels. The impact of new treatments will lead to a significant rise in global revenues in the market. The addition of further indications for these new products at a later date would allow for further expansion of their use.
To request a free report overview please email Sara Peerun: sara.peerun@visiongain.com or call her on +44 207 336 6100
The lead analyst of the report commented “Visiongain believes the major drivers of growth in the global cholesterol-lowering drugs market will be: increasing demand for cholesterol-lowering drugs due to population growth and the increasing prevalence of high cholesterol, improvements in the management and treatment of high cholesterol, increasing healthcare expenditure, especially in a number of emerging economies and he launch of new drugs such as PCSK9 inhibitors”
Leading companies featured in the report include: AstraZeneca, Merck & Co, Pfizer, Kowa Company, Daiichi Sankyo, AbbVie, Novartis, Sanofi, Amgen, Bristol-Myers Squibb (BMS).
You may download free sample pages on this time critical report by clicking on this link:
https://www.visiongain.com/Report/1980/Global-Cholesterol-Lowering-Drugs-Market-2017-2027
To request a free report overview please email Sara Peerun: sara.peerun@visiongain.com or call her on +44 207 336 6100
Companies mentioned in this report include:
Abbott Laboratories
AbbVie
Accord Healthcare
Aegerion Pharmaceuticals
Alcon
Algorithm SAL
Allergan
Alynlam Pharmaceuticals
Amgen
Apotex
Astellas Pharma
AstraZeneca
Aurobindo
BASF
Bayer
Biomarin Pharmaceuticals
Blu Caribe
Bristol-Myers Squibb
Ciba-Geigy
Daiichi Sankyo
DalCor Pharmaceuticals
Dezima Pharma
Dr Reddy’s Laboratories
EGIS Pharmaceuticals
Eli Lilly
Esperion Therapeutics
Eisai
Fresenius Medical Care
Genzyme Corporation
Glenmark
Hetero Laboratories
Impax Laboratories
Intas Pharmaceuticals
Isis Pharmaceuticals
JW Pharmaceutical
Kaneka
Kowa
Kremers Urban Pharmaceuticals
Lek
Lupin
Merck and Co.
Micro Laboratories
Miltenyi-Biotec
Mylan
Novartis
Par Pharmaceuticals
Pfizer
ProEthic Pharmaceuticals
ProNova BioPharma
Ranbaxy
Reckitt Benckiser
Recordati
Regeneron
Roche
Sandoz
Sanofi
Serometrix
Shionogi
Solvay
Sun Pharma
Teva
Torrent Pharmaceuticals
UCB
Valeant
Warner-Lambert
Wockhardt
Zydus Cadila
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100
About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.